[HTML][HTML] Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment

JC Restrepo, D Dueñas, Z Corredor, Y Liscano - Cancers, 2023 - mdpi.com
Simple Summary In the field of non-small cell lung cancer (NSCLC), there have been
significant advancements in genomic data and bioinformatics tools, which have improved …

Anoverview of biomedical applications for gold nanoparticles against lung cancer

V Kumari, S Vishwas, R Kumar, V Kakoty… - Journal of Drug Delivery …, 2023 - Elsevier
Lung cancer (LC) is the commonest class of cancer worldwide and is the reason for more
deaths than any other type. Treatment of LC using conventional therapy has some …

[HTML][HTML] Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug …

S Akash, S Bibi, P Biswas, N Mukerjee, DA Khan… - Frontiers in …, 2023 - frontiersin.org
Breast and lung cancer are two of the most lethal forms of cancer, responsible for a
disproportionately high number of deaths worldwide. Both doctors and cancer patients …

[HTML][HTML] An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer

J Rajkovic, R Novakovic, J Grujic-Milanovic… - Frontiers in …, 2023 - frontiersin.org
Calotropin is a pharmacologically active compound isolated from milkweed plants like
Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the …

Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment

NK Horvat, S Chocarro, O Marques, TA Bauer, R Qiu… - ACS …, 2024 - ACS Publications
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor
(TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor …

[HTML][HTML] The lung microbiome in COPD and lung cancer: Exploring the potential of metal-based drugs

M O'Shaughnessy, O Sheils, AM Baird - International Journal of …, 2023 - mdpi.com
Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most
prevalent and debilitating respiratory diseases worldwide, both associated with high …

[HTML][HTML] Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer

MT Le, HT Nguyen, XH Nguyen, XH Do, BT Mai… - Heliyon, 2023 - cell.com
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80%–85% of total cases and leading to millions of deaths worldwide. Drug resistance is the …

COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment …

H Abdel-Razeq, B Sharaf, MJ Al-Jaghbeer… - Journal of Thrombosis …, 2023 - Springer
Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …

[HTML][HTML] PET radiomics and response to immunotherapy in lung cancer: A systematic review of the literature

L Evangelista, F Fiz, R Laudicella, F Bianconi… - Cancers, 2023 - mdpi.com
Simple Summary The present review was performed in order to provide a comprehensive
overview of the existing literature concerning the applications of positron emission …

[HTML][HTML] Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

X Zhang, X Wang, L Hou, Z Xu, Y Liu… - Frontiers in …, 2023 - frontiersin.org
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint
inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy …